BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9257325)

  • 1. PET-pharmacokinetics of 18F-octreotide: a comparison with 67Ga-DFO- and 86Y-DTPA-octreotide.
    Wester HJ; Brockmann J; Rösch F; Wutz W; Herzog H; Smith-Jones P; Stolz B; Bruns C; Stöcklin G
    Nucl Med Biol; 1997 May; 24(4):275-86. PubMed ID: 9257325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological characterisation of [67Ga] or [68Ga] labelled DFO-octreotide (SDZ 216-927) for PET studies of somatostatin receptor positive tumors.
    Stolz B; Smith-Jones PM; Albert R; Reist H; Mäcke H; Bruns C
    Horm Metab Res; 1994 Oct; 26(10):453-9. PubMed ID: 7851867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.
    Smith-Jones PM; Stolz B; Albert R; Ruser G; Briner U; Mäcke HR; Bruns C
    Nucl Med Biol; 1998 Apr; 25(3):181-8. PubMed ID: 9620621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
    Anderson CJ; Pajeau TS; Edwards WB; Sherman EL; Rogers BE; Welch MJ
    J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
    Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
    J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
    Bakker WH; Krenning EP; Reubi JC; Breeman WA; Setyono-Han B; de Jong M; Kooij PP; Bruns C; van Hagen PM; Marbach P
    Life Sci; 1991; 49(22):1593-601. PubMed ID: 1658516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies.
    Smith-Jones PM; Stolz B; Bruns C; Albert R; Reist HW; Fridrich R; Mäcke HR
    J Nucl Med; 1994 Feb; 35(2):317-25. PubMed ID: 8295005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New octreotide derivatives for in vivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET).
    Mäcke HR; Smith-Jones P; Maina T; Stolz B; Albert R; Bruns C; Reist H
    Horm Metab Res Suppl; 1993; 27():12-7. PubMed ID: 8392486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide.
    Bass LA; Lanahan MV; Duncan JR; Erion JL; Srinivasan A; Schmidt MA; Anderson CJ
    Bioconjug Chem; 1998; 9(2):192-200. PubMed ID: 9548534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (2-[18F]fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice.
    Guhlke S; Wester HJ; Bruns C; Stöcklin G
    Nucl Med Biol; 1994 Aug; 21(6):819-25. PubMed ID: 9234331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
    Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
    Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
    Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
    Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates.
    Schottelius M; Wester HJ; Reubi JC; Senekowitsch-Schmidtke R; Schwaiger M
    Bioconjug Chem; 2002; 13(5):1021-30. PubMed ID: 12236784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides.
    Vallabhajosula S; Moyer BR; Lister-James J; McBride BJ; Lipszyc H; Lee H; Bastidas D; Dean RT
    J Nucl Med; 1996 Jun; 37(6):1016-22. PubMed ID: 8683294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.